Mistye Taylor
Smyrna, TNNPI 1548429798
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,288 of the $6,260 with a category attached, or 68.5%. 34 manufacturers reported payments, led by Intuitive Surgical at 30.8% of the total. Reporting peaked in 2022 at $2,493 and has fallen 50.2% since, to $1,242 in 2025.
Across 245 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- AbbVie$724
- Astellas Pharma US Inc$469
- Millicent US Inc$343
- Organon$329
- Mayne Pharma Commercial LLC$287
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,61626%
- Food & beverage$4,28868%
- Education$3435%
- Gifts$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $1,931 |
| AbbVie(2 entities) | 56 | $724 |
| Astellas Pharma US Inc | 16 | $469 |
| Millicent US Inc | 10 | $343 |
| Organon | 17 | $329 |
| Mayne Pharma Commercial LLC | 23 | $287 |
| Sage Therapeutics, LLC | 16 | $274 |
| Exeltis, USA Inc. | 13 | $200 |
| Shield Therapeutics Inc | 8 | $163 |
| Coopersurgical, Inc. | 9 | $146 |
| Daiichi Sankyo Inc. | 6 | $111 |
| Caldera Medical, Inc | 1 | $106 |
| Channel Medsystems, Inc. | 1 | $106 |
| Scynexis, Inc. | 5 | $100 |
| Novo Nordisk | 5 | $95 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Mylan Pharmaceuticals Inc. | 6 | $83 |
| Lilly USA, LLC | 5 | $78 |
| Stryker | 1 | $75 |
| Bayer | 4 | $74 |
| Hologic Sales And Service, LLC | 4 | $63 |
| Roche Diagnostics Corporation | 3 | $59 |
| Therapeuticsmd, Inc. | 4 | $59 |
| Agile Therapeutics, Inc. | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 2 | $49 |
| Currax Pharmaceuticals LLC | 3 | $39 |
| Lupin Inc. | 2 | $33 |
| Olympus America Inc. | 1 | $22 |
| Pfizer | 1 | $19 |
| Cepheid | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Optumhealth Care Solutions, LLC | 1 | $14 |
| Evofem Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,798
- Desara$106
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 21 | $2,007 |
| ValacyclovirValacyclovir Hcl | 12 | $424 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.